Extended Data Fig. 4: ctDNA levels in the INSPIRE sub-cohorts and correlation with RECIST tumor measurements.
ctDNA levels (MTM/mL) at baseline a, and at cycle 3 b, as well as the fold-change in ctDNA levels from baseline to cycle 3 (∆ctDNAC3) c, are shown for each of the sub-cohorts: Squamous cell cancer of head and neck (SCCHN, cohort A), triple negative breast cancer (TNBC, cohort B), high grade serous ovarian cancer (HGSOC, cohort C), malignant melanoma (MM, cohort D), and mixed solid tumors (MST, cohort E). Box plots represent the median, upper and lower quartiles of each distribution with whiskers showing the limits of the distribution (1.5 times the interquartile range). The N (patients) for each group is shown in the top axis. Two-sided Kruskal-Wallis test p-values are shown for (a–c). d, Relationship between ctDNAB and RECIST 1.1 target lesion sum of tumor measurements (N = 94 patients). Scatter plot with Spearman correlation coefficient (R) and two-sided p-value are shown. The poor correlation in this diverse cohort of advanced cancers suggests that ctDNA may provide complementary information to RECIST tumor measurements. Of note, RECIST target lesion sum of tumor measurements does not incorporate measurements from non-target lesions.
